Valsartan

VALSARTAN

Thank you to all registrants who have reached out to us regarding our class action lawsuit against the manufacturers of contaminated valsartan drugs. As we investigate this matter further, we are now interested in hearing from individuals who have been prescribed pills manufactured by either Actavis Pharma Company or Mylan Pharmaceuticals ULC. If you have been affected by products from either of these companies, we ask that you please contact our office.

Current Status
Overview

Current Status

Certification was dismissed by Mr. Justice Perell on August 12, 2022, see here, and the Plaintiff’s appeal was dismissed by the Ontario Court of Appeal on March 27, 2024, see here; 2024 ONCA 220 (CanLII) | Palmer v. Teva Canada Limited | CanLII.

The decisions by the Courts are final. However, the Courts did not consider or dismiss claims by class members that may have developed cancer as a result of consuming recalled Valsartan.

RHE, along with other firms across Canada, have commenced proceedings relating to cancer that may have been caused by ingestion of contaminated Valsartan. Please fill out our form to receive further updates about this matter.

Overview

Rice Harbut Elliott LLP has commenced proceedings in an anticipated class action lawsuit, representing Canadians who were prescribed drugs containing the ingredient valsartan. Drugs containing valsartan are used to treat patients with high blood pressure to help prevent heart attacks and stroke. These drugs are also used in patients who have had heart failure or a recent heart attack. The affected drugs were reportedly contaminated with a potential carcinogen. These drugs were recalled by Health Canada on July 9, 2018. At present, the recall involves the following valsartan products:

Product name/Active Pharmaceutical Ingredient	DIN	Strength	Lot #	Date Added
TEVA-VALSARTAN/HCTZ TABLETS	02356996	80/12.5 mg	35211136A	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357003	160/12.5 mg	35211335A	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357003	160/12.5 mg	35211844R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357011	160/25 mg	35210937R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357011	160/25 mg	35210938R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357011	160/25 mg	35210939R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357011	160/25 mg	35210940R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS	02357038	320/12.5 mg	35211546R	August 17, 2018
TEVA-VALSARTAN/HCTZ TABLETS PP 30s	02357046	320/25 mg	35212731R	July 9, 2018
ACT-VALSARTAN 40MG FC TABLETS 100	02337487	40 mg	K47338	July 9, 2018
ACT-VALSARTAN 80MG FC TABLETS 100	02337495	80 mg	K45370	July 9, 2018
ACT-VALSARTAN 80MG FC TABLETS 100	02337495	80 mg	K47652	July 9, 2018
ACT-VALSARTAN 80MG FC TABLETS 100	02337495	80 mg	K47653	July 9, 2018
ACT-VALSARTAN 80MG FC TABLETS 100	02337495	80mg	K47654	July 9, 2018
ACT-VALSARTAN 160MG FC TABLETS 100	02337509	160 mg	K39691	July 9, 2018
ACT-VALSARTAN 160MG FC TABLETS 100	02337509	160 mg	K44167	July 9, 2018
ACT-VALSARTAN 160MG FC TABLETS 100	02337509	160 mg	K47657	July 9, 2018
ACT-VALSARTAN 160MG FC TABLETS 100	02337509	160 mg	K47658	July 9, 2018
ACT-VALSARTAN 320MG FC TABLETS 100	02337517	320 mg	K44166	July 9, 2018
ACT-VALSARTAN 320MG FC TABLETS 100	02337517	320 mg	K45371	July 9, 2018
SANDOZ VALSARTAN 40 MG	02356740	40 mg	All lots	July 9, 2018
SANDOZ VALSARTAN 80 MG	02356759	80 mg	All lots	July 9, 2018
SANDOZ VALSARTAN 160 MG	02356767	160 mg	All lots	July 9, 2018
SANDOZ VALSARTAN 320 MG	02356775	320 mg	All lots	July 9, 2018
SANIS VALSARTAN 40 MG	02366940	40 mg	All lots	July 9, 2018
SANIS VALSARTAN 80 MG	02366959	80 mg	All lots	July 9, 2018
SANIS VALSARTAN 160 MG	02366967	160 mg	All lots	July 9, 2018
SANIS VALSARTAN 320 MG	02366975	320 mg	All lots	July 9, 2018
PRO DOC LIMITEE VALSARTAN 40 MG	02367726	40 mg	All lots	July 9, 2018
PRO DOC LIMITEE VALSARTAN 80 MG	02367734	80 mg	All lots	July 9, 2018
PRO DOC LIMITEE VALSARTAN 160 MG	02367742	160 mg	All lots	July 9, 2018
PRO DOC LIMITEE VALSARTAN 320 MG	02367750	320 mg	All lots	July 9, 2018
SIVEM PHARMACEUTICAL ULC VALSARTAN 40 MG	02384523	40 mg	All lots	July 9, 2018
SIVEM PHARMACEUTICAL ULC VALSARTAN 80 MG	02384531	80 mg	All lots	July 9, 2018
SIVEM PHARMACEUTICAL ULC VALSARTAN 160 MG	02384558	160 mg	All lots	July 9, 2018
SIVEM PHARMACEUTICAL ULC VALSARTAN 320 MG	02384566	320 mg	All lots	July 9, 2018

The full details of the Health Canada recall can be found here.

Our firm is seeking compensation for persons who received any of the above-listed drugs. Damages will be sought for individuals who became diagnosed with cancer and other individuals who received the drugs that were recalled. The latter group may be entitled to compensation pursuant to B.C. consumer protection legislation.

If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

Valsartan Form

Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing reception@rhelaw.com

Class Action Form

Contact Information

Name *

First

Last

Email *

Phone

FAX

Address (unit no., building/house number, street name)

City/ Town

Province

Postal Code

SUBJECT *

DATE OF BIRTH *

PERSONAL HEALTH NUMBER *

DATE OF PRESCRIPTION *

DATE THAT YOU SOUGHT MEDICAL TREATMENT FOR YOUR SYMPTOMS

ARE YOU AWARE OF THE CANADIAN VALSARTAN RECALL? *

WERE YOU TAKING THE DRUGS PRIOR TO THE HEALTH CANADA PUBLIC ADVISORY ON JULY 9, 2018? *

WHEN DID YOU BECOME AWARE OF THE RECALL? *

HAVE YOU BEEN DIAGNOSED WITH CANCER? *

DID YOU TAKE ONE OF THE RECALLED LOTS OF VALSARTAN IDENTIFIED ABOVE? *

PLEASE LIST ALL THE SYMPTOMS YOU EXPERIENCED.

OTHER COMMENTS

Consent *

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that I can unsubscribe to these emails at any time. I understand that some of the personal information that I provide may be stored or processed outside of British Columbia and/or Canada, on a US server, and will be kept confidential, subject to the potential that a foreign state may seek to access the data for “lawful access” purposes. If you have any questions about RHE’s policies and practices regarding service providers outside Canada, or about the collection, use, disclosure or storage of personal information by the service providers outside Canada, please contact reception@rhelaw.com.

Custom Captcha *